Loading…
Reported covered position: Pol. Ad. (Sen. Bill Cassidy, LA) LD (Rep. John Shimkus, IL-15) Sr Policy Advisor (Sen. Mark Kirk, IL) LA (Rep. Judy Biggert, IL-13) Leg. Corr./LA (Rep. Michele Bachmann, MN-06) Staff Asst./Leg. Corr.(Rep. Dennis Hastert, IL-14)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2026 · third_quarter · Q3
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Source: Senate LDA
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (s.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (S.1717) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Cybersecurity for Healthcare Industry AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Drought Resilient Infrastructure Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Cybersecurity for Healthcare Industry AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
Southern Utah Open OHV Areas Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
Southern Utah Open OHV Areas Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Consolidated Appropriations Act, 2023
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Consolidated Appropriations Act, 2023
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Consolidated Appropriations Act, 2023
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Consolidated Appropriations Act, 2023
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Consolidated Appropriations Act, 2023
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Iran Responsible Reporting Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
National Aeronautics and Space Administration Authorization Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
National Aeronautics and Space Administration Authorization Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
National Aeronautics and Space Administration Authorization Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
National Aeronautics and Space Administration Authorization Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Consolidated Appropriations Act, 2023
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R. 6, SUPPORT For Patients and Communities Act (Sunshine) H.R.2617 - Consolidated Appropriations Act, 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R. 6, SUPPORT For Patients and Communities Act (Sunshine) H.R.2617 - Consolidated Appropriations Act, 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
Ensuring Patient Access to Critical Breakthrough Products Act of 2021
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
Meaningful Access to Federal Health Plan Claims Data Act of 2021
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
Meaningful Access to Federal Health Plan Claims Data Act of 2021
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Financial Literacy to Financial Freedom Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Whistleblower Protection Extension Act of 2017
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Iran Responsible Reporting Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Iran Responsible Reporting Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Iran Responsible Reporting Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
SUPPORT for Patients and Communities Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R. 6, SUPPORT For Patients and Communities Act (Sunshine) H.R.2617 - Consolidated Appropriations Act, 2023
SUPPORT for Patients and Communities Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
SUPPORT for Patients and Communities Act
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
National Aeronautics and Space Administration Authorization Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
National Aeronautics and Space Administration Authorization Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
National Aeronautics and Space Administration Authorization Act of 2018
Client: EDWARDS LIFESCIENCES LLC · Firm: EDWARDS LIFESCIENCES, LLC
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2026 · second_quarter · Q2
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development
Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2026 · first_quarter · Q1
Tariffs
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · fourth_quarter · Q4
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Japan Reimbursement of Medical Devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · third_quarter · Q3
Corporate Tax Reform Proposals
Tariffs Japan Reimbursement of Medical Devices
Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · second_quarter · Q2
Ensuring Patient Access to Critical Breakthrough Products (S.1717) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (s.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2025 · first_quarter · Q1
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2024 · fourth_quarter · Q4
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Supply Chain Proposals
Corporate Tax Reform Proposals
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2024 · third_quarter · Q3
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Cybersecurity for Healthcare Industry AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2024 · second_quarter · Q2
Use of Ethylene Oxide in Medical Device Sterilization
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2024 · first_quarter · Q1
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain Japan Reimbursement of Medical Devices
Use of Ethylene Oxide in Medical Device Sterilization
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2023 · second_quarter · 2A
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Use of Ethylene Oxide in Medical Device Sterilization
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2023 · fourth_quarter · Q4
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2023 · third_quarter · Q3
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain Japan Reimbursement of Medical Devices
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2023 · second_quarter · Q2
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain
Corporate Tax Reform Proposals
Dept. of Veterans Affairs TAVR Access
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2023 · first_quarter · Q1
Use of Ethylene Oxide in Medical Device Sterilization
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2022 · fourth_quarter · Q4
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R. 6, SUPPORT For Patients and Communities Act (Sunshine) H.R.2617 - Consolidated Appropriations Act, 2023
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2022 · third_quarter · Q3
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain
Use of Ethylene Oxide in Medical Device Sterilization
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
EDWARDS LIFESCIENCES LLC via EDWARDS LIFESCIENCES, LLC
2022 · second_quarter · Q2
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development
Corporate Tax Reform Proposals
Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Corporate Tax Reform Proposals
Tariffs
Veterans Access to MedTech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Corporate Tax Reform Proposals
Use of Ethylene Oxide in Medical Device Sterilization
Supply Chain Proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Corporate Tax Reform Proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1961) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting Coverage with Evidence Development
Corporate Tax Reform Proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Corporate Tax Reform Proposals
Dept. of Veterans Affairs TAVR Access
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Corporate Tax Reform Proposals
Use of Ethylene Oxide in Medical Device Sterilization
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain Japan Reimbursement of Medical Devices
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Use of Ethylene Oxide in Medical Device Sterilization
Dept. of Veterans Affairs TAVR Access
Corporate Tax Reform Proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Use of Ethylene Oxide in Medical Device Sterilization
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Corporate Tax Reform Proposals
Dept. of Veterans Affairs TAVR Access
Supply Chain Proposals The CHIPS Act of 2022 China Market Access and Supply Chain
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) Transitional Coverage for Emerging Technologies (TCET) rule Policies promoting medical innovation Heart Valve Disease Awareness Implementation of PL-115-201, FDA Reauthorization Act of 2017 Cybersecurity for Healthcare Industry FDA Reauthorization for 2022/FDA User Fees Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 1193, The Cardiovascular Advances in Research and Opportunities Legacy Act CAROL Act Inspection Modernization Emerging Signals Shortage Reporting S.3799 PREVENTS Pandemic Act Coverage with Evidence Development H.R.2617 - Consolidated Appropriations Act, 2023
Use of Ethylene Oxide in Medical Device Sterilization
Corporate Tax Reform Proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.4043) (includes MCIT Proposed Rule) Heart Valve Disease Awareness Coronavirus Preparedness and Response Provisions (PHE) Health Equity Issues Coverage with Evidence Development HR 5394 Registry Access to Medicare Claims Data includes Coverage with Evidence Development provisions H.R. 6, SUPPORT For Patients and Communities Act (Sunshine)
Corporate Tax Reform Proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Supply Chain Proposals China Market Access and Supply Chain
Corporate Tax Reform Proposals
Use of Ethylene Oxide in Medical Device Sterilization
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of